X

Trial Profile

Investigating the safety and tolerability of PMR-116 in Patients with Advanced Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PMR-116 (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Pimera

Most Recent Events

28 Feb 2022 Accrual to date is 15 participants as per Australian New Zealand Clinical Trials Registry record.
02 Feb 2022 according to a Pimera Therapeutics media release, this study is currently in the dose escalation stage of this study being conducted in Australia.
02 Feb 2022 Status changed from not yet recruiting to recruiting, according to a Pimera Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com